Dr Cohen on Treatment Considerations for Relapsed/Refractory MCL
Jonathon B. Cohen, MD, MS, discusses treatment considerations for mantle cell lymphoma and the role of pirtobrutinib in the management of this disease.
Source: onclive.com
Jonathonb Cohen News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jonathonb Cohen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jonathonb Cohen Today - Breaking & Trending Today
Dr Cohen on Available Treatments For MCL
Jonathon B. Cohen, MD, MS, discusses the background of the BRUIN study of pirtobrutinib in previously treated patients with mantle cell lymphoma.
Source: onclive.com
Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL
Jonathon B. Cohen, MD, MS, expands on updated data from the BRUIN trial of pirtobrutinib in patients with relapsed BTK-exposed mantle cell lymphoma.
Source: onclive.com
Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL
Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.
Source: onclive.com
Pirtobrutinib Displays Activity in Relapsed/Refractory MCL Following Covalent BTK Inhibitor Therapy
Pirtobrutinib demonstrated promising efficacy and a tolerable safety profile in heavily pretreated patients with relapsed/refractory mantle cell lymphoma who received prior therapy with a covalent BTK inhibitor.
Source: onclive.com